From defense to offense: A new paradigm for life science supply chains
The life science industry is innovating at an unprecedented pace. However, its supply chains are struggling to keep up, according to a new white paper from supply chain consultancy AIM.
The struggles being faced in today’s supply chains in life sciences stem from a model built for a different era – one defined by stability, predictability, and incremental change. That era is over, highlights the AIM report.
What is needed now is a supply chain capability that shifts from defence to offence: strategically integrated with the business, designed for adaptability, and focused on creating value rather than merely managing operational efficiency.
The current business environment
Life science companies are navigating a striking double challenge: therapeutic innovations have never been stronger, yet the operating environment has never been more demanding. As pipelines tilt towards complex biologics and advanced, personalized therapies, companies are reaching more patients with breakthrough treatments in key disease areas such as metabolic, oncology, and neuroscience.
At the same time, profit margins face pressure from both revenue and cost side, with increasing importance of outcomes-based contracts, reference pricing, and tighter impact assessments.
Supply chain as a strategic, value-driven capability
There is now a widening gap between business requirements and the reality of today’s supply chain operations. While the industry is expanding towards breakthrough treatments and digital patient solutions, supply chain management often remains stuck in a state of average maturity and limited aspiration.
Advanced planning systems generate deterministic plans, which create endless alerts, and planners spend their days chasing these alerts and firefighting, rather than strategically improving preparedness, agility, and resilience. Too often, supply chain is still not perceived as strategic, and the function struggles to attract the best talent in the company.
Change is needed. To master the new environment, supply chain leaders must step up and take a more strategic role: excellent scientific innovation relies on flawless scale-up and resilient supply chain design. State-of-the-art commercial growth strategies need the right balance of reliable, cost-effective, and flexible delivery and service.
In other words, supply chain must according to the authors move from defense to offense, from efficiency in moments of stability to effectiveness in adapting to change.
From defense to offense: the target supply chain operating model
If the current model is built for stability, the ‘target model’ must be built for adaptability to market needs and uncertainty in the global supply network. This does not mean abandoning efficiency, it means redefining what the supply chain is optimized for.
No decision in life science supply chain carries higher stakes or greater uncertainty than committing supply ahead of a major launch or market event. Making these decisions based on point forecasts and deterministic supply plans ignores the full range of outcomes that are genuinely possible.
Processes across plan, source, make, deliver, and return, are the backbone of any supply chain. Yet too often they are run on a case-by-case basis, are highly person-dependent and manual, and tie up the whole team in issue resolution rather than forward-looking optimization. The future of supply chains, however, is rules-based and parametric: companies must put clear rules and thresholds in place, trust the system, and manage only the exceptions.
Leading supply chain organizations are defining a broader, more business-relevant performance framework. The first step is adding metrics for adaptability and strategic readiness, like launch readiness scores, end-to-end time-to-supply for new products, network flexibility indices, and the speed with which organization can respond to unplanned demand or supply disruptions.
The most ambitious supply chain leaders go further. They translate their contribution directly into business bottom-line metrics that matter most to the organization.
How to start – 5 priority actions for leaders
Moving from a defense to offense strategy requires a deliberately different approach: a strategic integration with the business, a stronger connection with the external ecosystem, a different planning philosophy and new ways of measuring and communicating value.
AIM’s white paper outlines five essential areas of action:
1. Develop a practical vision for offense
The starting point is not a technology investment or a reorganization; it is a conversation. Supply chain leaders need to engage their peers in commercial, finance, regulatory, and procurement to explore, in concrete terms, how the supply chain can drive greater business value from a strategic role.
2. Foster and role model the mindset shift
This means involving the supply chain leadership team in the conceptual work, making them co-authors of the transformation rather than passive recipients of a new operating model handed down from above.
3. Establish clear ground rules
Establishing explicit ground rules with commercial, manufacturing, and finance is a strategic prerequisite so the supply chain team can redirect its energy from short-term firefighting toward structural improvement, risk anticipation, and value creation.
4. Upskill your team to enable the step up
The offense model places different demands on supply chain talent. Technical competence in planning systems and analytical tools remains important, but it is no longer sufficient. What differentiates leaders in the new model is the ability to orchestrate stakeholders across the end-to-end value chain, drive clear decisions under uncertainty, and communicate supply chain implications in the language of business strategy.
5. Redefine how supply chain value is measured and communicated
Supply chain leaders should move beyond the narrative that performance is best expressed through operational metrics alone and instead, build a concise, business-facing performance story.
Conclusion
The supply chain model built for stability is no longer sufficient for an environment defined by volatility, margin pressure, complex therapies, changing regulations, and rising expectations from patients, customers, and partners. The supply chains that will succeed are those that are strategically integrated with the business, designed for uncertainty, connected to external signals, governed by disciplined processes, and measured by the value they create.
